Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"The new year holds a great deal of promise for the field of regenerative medicine, with companies like NEO at the forefront." (12/30/14) NeoStem Inc. - The Life Sciences Report Interview with Steve Brozak More >
Scott Henry is the head of healthcare research and a senior research analyst with ROTH Capital Partners, covering the specialty pharmaceutical sector. He came to ROTH Capital from OppenheimerFunds, where he led coverage of the U.S. pharmaceutical sector. He has also been affiliated with Thomas Weisel Partners, ABN AMRO and Leerink Swann & Co. His coverage universe has included specialty pharmaceuticals, large-cap pharmaceuticals, biotech and selective medical device names. He has 12 years of sellside experience. Henry was ranked #2 in The Wall Street Journal's "Best on the Street" stock-picking survey in 2010 and #3 on the Forbes/Zacks Investment Research "Best Analysts" list for the Drugs category in 2010. His investment views have been cited in The Wall Street Journal and The New York Times and he has made frequent appearances on CNBC, CBS Marketwatch, and Bloomberg. Henry attended the University of Rhode Island and received a master's degree in business administration with distinction from Cornell University.
Six Opportunities in the Specialty Pharmaceutical Space: Scott Henry (11/7/13) The specialty pharmaceuticals universe encompasses a variety of technologies, among them innovative drug delivery systems and unique pain management and orphan disease treatments. In this interview with The Life Sciences Report, Scott Henry of ROTH Capital Markets touts the value of "sound business models" in the specialty pharma space, and names six companies with interesting prospects and/or stock-moving catalysts on the horizon.
"BDSI's buprenorphine product for chronic pain could be a $500M+/year revenue-generating drug if approved." (11/7/13) BioDelivery Sciences International Inc. - The Life Sciences Report Interview with Scott Henry More >
"CPRX is an emerging biotechnology company in the white hot space of orphan drug medicines." (11/7/13) Catalyst Pharmaceutical Partners Inc. - The Life Sciences Report Interview with Scott Henry More >
"If all goes well, CUR's NSI-189 product will move into Phase 2 development in Q2/15, so that is a good advancement opportunity." (1/22/15) Neuralstem Inc. - The Life Sciences Report Interview with Edward Stopke More >
"ATHX completed enrollment in its Phase 2 stroke study before the new year, so the first 90-day results will emerge in Q1/15E." (1/22/15) Athersys Inc. - The Life Sciences Report Interview with Edward Stopke More >
"The research synergy with Gilead and Merck could prove fruitful for RNN in terms of acquisition potential." (1/22/15) Rexahn Pharmaceuticals Inc. - The Life Sciences Report Interview with Edward Stopke More >